The case for & against
Bull & Bear analysis
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical device company that focuses on providing innovative solutions for patients suffering from obstructive sleep apnea (OSA), primarily through its Inspire therapy platform. The company has established itself as a key player in the sleep health sector, leveraging advanced technology to improve patient outcomes. Recently, it has launched the Inspire 5 system, which is positioned to enhance treatment efficacy by addressing complications faced in prior versions. The ongoing transition to this product and its market penetration are critical components of its growth strategy.
Bull says
- ↑100k+ patients treated – strong adoption in underserved OSA market
- ↑79.5% responder rate and 20% shorter surgical times in Inspire 5 trial
- ↑Q1’26 adj EBITDA margin at 17.5%, up on improving efficiency
- ↑$400 M cash, no debt supports growth investments
- ↑Proactive marketing and clinician education boosting device uptake
- ↑Positive liquidity and profitability factors underpin growth outlook
Bear says
- ↓Coding and reimbursement uncertainty may trim $120–150 M of 2026 revenue
- ↓Inspire 5 rollout delays drove a 15% YoY rise in operational expenses
- ↓GLP-1 therapy growth could divert patient leads from Inspire
- ↓Physician engagement risk amid evolving reimbursement models
- ↓2026 revenue guidance cut to $825–875 M from prior $900–910 M
- ↓Negative growth and momentum factors signal execution challenges
Investment themes with INSP
Devices and instruments for medical treatment
Earnings Call · Q1 2025 · Mgmt. Guidance
Transcript signals
Bull points
- Total revenue for the quarter was $201.3 million, a 23% increase from the $164 million generated in the first quarter of 2024.
- U.S. revenue in the quarter was $193.6 million, an increase of 24% from the $155.8 million in the prior year period.
- This represented diluted net income per share of $0.10 compared to a net loss of $0.34 in the first quarter of 2024.
Bear points
- Revenue outside the U.S. was $7.7 million, which was a 6% decrease year over year.
- Total operating expenses for the quarter were 172.1 million, an increase of 11% as compared to 154.5 million in the first quarter of 2024.
- For centers, this process includes a contract amendment, implementation of the new physician programmer, and working through their INSPIRE IV inventory, which suggests challenges in the transition.